English
Значимость параметра аутофлуоресценции кожи в стратификации риска летальности и сердечно- сосудистых событий у пациентов, получающих программный гемодиализ
DOI: https://dx.doi.org/10.18565/therapy.2025.1.125-133
Д.Ю. Коновалова, П.А. Лебедев, М.Н. Жарков
1) ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России; 2) ГБУЗ «Самарская областная клиническая больница им. В.Д. Середавина»
Литература
1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease 2017. Lancet. 2020; 395(10225): 709–33. https://doi.org/10.1016/S0140-6736(20)30045-3. PMID: 32061315. PMCID: PMC7049905. 2. McQueen R.B., Farahbakhshian S., Bell K.F. et al. Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. 2017; 20(6): 585–91. https://doi.org/10.1080/13696998.2017.1288127. PMID: 28128669. 3. Шилов Е.М., Шилова М.М., Румянцева Е.И. с соавт. Нефрологическая служба Российской Федерации 2023: часть 1. Заместительная почечная терапия. Клиническая нефрология. 2024; 16(1): 5–14. (Shilov E.M., Shilova M.M., Rumyantseva E.I. et al. Nephrological service of the Russian Federation 2023: Part I. Renal replacement therapy. Klinicheskaya nefrologiya = Clinical Nephrology. 2024; 16(1): 5–14 (In Russ.)). https://doi.org/10.18565/nephrology.2024.1.5-14. EDN: DAZGYH. 4. Manns B., Hemmelgarn B., Tonelli M. et al.; for Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease. The cost of care for people with chronic kidney disease. Can J Kidney Health Dis. 2019; 6: 2054358119835521. https://doi.org/10.1177/2054358119835521. PMID: 31057803. PMCID: PMC6452586. 5. O’Lone E., Viecelli A.K., Craig J.C. et al.; SONG-HD CVD Consensus Workshop Investigators. Establishing core cardiovascular outcome measures for trials in hemodialysis: Report of an international consensus workshop. Am J Kidney Dis. 2020; 76(1): 109–20. https://doi.org/10.1053/j.ajkd.2020.01.022. PMID: 32414662. 6. Давыдова Н.А., Лебедев П.А., Чернышев А.В. с соавт. Клиническое и прогностическое значение параметра аутофлуоресценции кожи у пациентов с ишемической болезнью сердца и заболеванием периферических артерий. Терапия. 2024; 10(2): 32–40. (Davydova N.A., Lebedev P.A., Chernyshev A.V. et al. Clinical and prognostic value of the skin autofluorescence parameter in coronary heart disease and peripheral arterial disease patients. Terapiya = Therapy. 2024; 10(2): 32–40 (In Russ.)). https://doi.org/10.18565/therapy.2024.2.32-40. EDN: NMIORV. 7. Salazar J., Navarro C., Ortega Á. et al. Advanced glycation end products: New clinical and molecular perspectives. Int J Environ Res Public Health. 2021; 18(14): 7236. https://doi.org/10.3390/ijerph18147236. PMID: 34299683. PMCID: PMC8306599. 8. Simm A. Protein glycation during aging and in cardiovascular disease. J Proteomics. 2013; 92: 248–59. https://doi.org/10.1016/j.jprot.2013.05.012. PMID: 23702329. 9. Yamamoto Y., Doi T., Kato I. et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci. 2005; 1043: 562–66. https://doi.org/10.1196/annals.1333.064. PMID: 16037279. 10. Forbes J.M., Yee L.T.L., Thallas V. et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004; 53(7): 1813–23. https://doi.org/10.2337/diabetes.53.7.1813. PMID: 15220206. 11. Petrica L., Vlad A., Gluhovschi G. et al. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: A cross-sectional study. J Diabetes Complications. 2015; 29(2): 230–37. https://doi.org/10.1016/j.jdiacomp.2014.11.014. PMID: 25511877. 12. Kandarakis S.A., Piperi C., Topouzis F., Papavassiliou A.G. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res. 2014; 42: 85–102. https://doi.org/10.1016/j.preteyeres.2014.05.002. PMID: 24905859. 13. Li J., Liu D., Sun L. et al. Advanced glycation end-products and neurodegenerative diseases: Mechanisms and perspective. J Neurol Sci. 2012; 317(1–2): 1–5. https://doi.org/10.1016/j.jns.2012.02.018. PMID: 22410257. 14. Meerwaldt R., Graaff R., Oomen P.H.N. et al. Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia. 2004; 47(7): 1324–30. https://doi.org/10.1007/s00125-004-1451-2. PMID: 15243705. 15. Reddy V.P., Aryal P., Darkwah E.K. Advanced glycation end products in health and disease. Microorganisms. 2022; 10(9): 1848. https://doi.org/10.3390/ microorganisms10091848. PMID: 36144449. PMCID: PMC9501837. 16. Tessier F.J. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris). 2010; 58(3): 214–19. https://doi.org/10.1016/j.patbio.2009.09.014. PMID: 19896783. 17. Rowan S., Bejarano E., Taylor A. Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(12): 3631–43. https://doi.org/10.1016/j.bbadis.2018.08.036. PMID: 30279139. PMCID: PMC6822271. 18. Xu B., Chibber R., Ruggiero D. et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003; 17(10): 1289–91. https://doi.org/10.1096/fj.02-0490fje. PMID: 12738813. 19. Hwang S.H., Kim H.Y., Zuo G. et al. Anti-glycation, carbonyl trapping and anti-inflammatory activities of chrysin derivatives. Molecules. 2018; 23(7): 1752. https://doi.org/10.3390/molecules23071752. PMID: 30018253. PMCID: PMC6099615. 20. Laurent S., Boutouyrie P. Arterial stiffness and hypertension in the elderly. Front Cardiovasc Med. 2020; 7: 544302. https://doi.org/10.3389/fcvm.2020.544302. PMID: 33330638. PMCID: PMC7673379. 21. Budoff M.J., Alpert B., Chirinos J.A. et al. Clinical applications measuring arterial stiffness: An expert consensus for the application of cardio ankle vascular index. Am J Hypertens. 2022; 35(5): 441–53. https://doi.org/10.1093/ajh/hpab178. PMID: 34791038. PMCID: PMC9088840. 22. Sakaguchi T., Yan S.F., Yan S.D. et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003; 111(7): 959–72. https://doi.org/10.1172/jci17115. PMID: 12671045. PMCID: PMC152587. 23. Makita Z., Radoff S., Rayfield E.J. et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991; 325(12): 836–42. https://doi.org/10.1056/NEJM199109193251202. PMID: 1875967. 24. Maasen K., van Greevenbroek M.M.J., Scheijen J.L.J.M. et al. High dietary glycemic load is associated with higher concentrations of urinary advanced glycation end products: The Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) Study. Am J Clin Nutr. 2019; 110(2): 358–66. https://doi.org/10.1093/ajcn/nqz119. PMID: 31240298. 25. Solbu M.D., Mjøen G., Mark P.B. et al. Predictors of atherosclerotic events in patient on haemodialysis: Post hoc analyses from the AURORA study. Nephrol Dial Transplant. 2018; 33(1): 102–12. https://doi.org/10.1093/ndt/gfw360. PMID: 27798199. 26. You X., Huang Y.Y., Wang Y. et al. Prediction model for cardiovascular disease risk in hemodialysis patients. Int Urol Nephrol. 2022; 54(5): 1127–34. https://doi.org/10.1007/s11255-021-02984-7. PMID: 34487297. 27. Epifânio A.P.S., Balbino K.P., Ribeiro S.M.R. et al. Clinical-nutritional, inflammatory and oxidative stress predictors in hemodialysis mortality: A review. Nutr Hosp. 2018; 35(2): 461–68. https://doi.org/10.20960/nh.1266. PMID: 29756982. 28. Soleymanian T., Niyazi H., Dehkordi S.N.J. et al. Predictors of clinical outcomes in hemodialysis patients: A multicenter observational study. Iran J Kidney Dis. 2017; 11(3): 229–36. PMID: 28575884. 29. Kitamura H., Yamada S., Hiyamuta H. et al. Serum alkaline phosphatase levels and increased risk of brain hemorrhage in hemodialysis patients: The Q-cohort study. J Atheroscler Thromb. 2022; 29(6): 923–36. https://doi.org/10.5551/jat.62885. PMID: 34108341. PMCID: PMC9174090. 30. Yang Y., Qin X., Li Y. et al. Relationship between serum uric acid and mortality risk in hemodialysis patients: A multicenter prospective cohort study. Am J Nephrol. 2020; 51(10): 823–32. https://doi.org/10.1159/000509258. PMID: 33070128. 31. Feldreich T., Nowak C., Fall T. et al. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. J Nephrol. 2019; 32(1): 111–19. https://doi.org/10.1007/s40620-018-0556-5. PMID: 30499038. PMCID: PMC6373380. 32. Bargnoux A.-S, Kuster N., Patrier L. et al. Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: Should we choose between hs-troponin I and hs-troponin T? Clin Chem Lab Med. 2016; 54(4): 673–82. https://doi.org/10.1515/cclm-2015-0071. PMID: 26457775. 33. Song Y.-H., Cai G.-Y., Xiao Y.-F., Chen X.-M. Risk factors for mortality in elderly haemodialysis patients: A systematic review and meta-analysis. BMC Nephrol. 2020; 21(1): 377. https://doi.org/10.1186/s12882-020-02026-x. PMID: 32867718. PMCID: PMC7457491. 34. Meerwaldt R., Hartog J.W.L., Graaff R. et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16(12): 3687–93. https://doi.org/10.1681/ASN.2005020144. PMID: 16280473. 35. Arsov S., Graaff R., van Oeveren W. et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: A review. Clin Chem Lab Med. 2014; 52(1): 11–20. https://doi.org/10.1515/cclm-2012-0832. PMID: 23612551. 36. Schwedler S.B., Metzger T., Schinzel R., Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002; 62(1): 301–10. https://doi.org/10.1046/j.1523-1755.2002.00423.x. PMID: 12081592. 37. Viramontes-Hörner D., Selby N.M., Taal M.W. Skin autofluorescence and malnutrition as predictors of mortality in persons receiving dialysis: A prospective cohort study. J Hum Nutr Diet. 2020; 33(6): 852–61. https://doi.org/10.1111/jhn.12764. PMID: 32383489. 38. Viramontes-Hörner D., Selby N.M., Taal M.W. The association of nutritional factors and skin autofluorescence in persons receiving hemodialysis. J Ren Nutr. 2019; 29(2): 149–55. https://doi.org/10.1053/j.jrn.2018.07.004. PMID: 30309781. 39. Viramontes-Hörner D., Selby N.M., Taal M.W. Factors associated with change in skin autofluorescence, a measure of advanced glycation end products, in persons receiving dialysis. Kidney Int Rep. 2020; 5(5): 654–62. https://doi.org/10.1016/j.ekir.2020.02.003. PMID: 32405587. PMCID: PMC7210606. 40. Viramontes-Hörner D., Selby N.M., Taal M.W. Prospective study of change in skin autofluorescence over time and mortality in people receiving hemodialysis. Kidney Int Rep. 2024; 9(7): 2110–16. https://doi.org/10.1016/j.ekir.2024.03.020. PMID: 39081750. PMCID: PMC1128444. 41. McIntyre N.J. Trend and monitoring of skin autofluorescence in patients receiving hemodialysis. Kidney Int Rep. 2024; 9(8): 2335–36. https://doi.org/10.1016/j.ekir.2024.06.016. PMID: 39156148. PMCID: PMC11328780. 42. Varikasuvu S.R., Sulekar H., Aloori S., Thangappazham B. The association of non-invasive skin autofluorescence measurements with cardiovascular and all-cause mortality in hemodialysis patients: A meta-analysis. Int Urol Nephrol. 2020; 52(9): 1757–69. https://doi.org/10.1007/s11255-020-02543-6. PMID: 32661621.
Об авторах / Для корреспонденции
Дарья Юрьевна Коновалова, аспирант кафедры терапии Института профессионального образования с курсом функциональной диагностики ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России. Адрес: 443099, г. Самара, ул. Чапаевская, д. 89.
E-mail: snowflake0605@mail.ru
ORCID: https://orcid.org/0009-0002-2964-2675
Петр Алексеевич Лебедев, д. м. н., профессор, заведующий кафедрой терапии Института профессионального образования c курсом функциональной диагностики ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России. Адрес: 443099, г. Самара, ул. Чапаевская, д. 89.
E-mail: palebedev@yahoo.com
ORCID: https://orcid.org/0000-0003-3501-2354
Михаил Николаевич Жарков, врач-трансфузиолог высшей категории, заведующий отделением переливания крови ГБУЗ «Самарская областная клиническая больница им. В.Д. Середавина», главный специалист минздрава Самарской области. Адрес: 443095, г. Самара, ул. Ташкентская, д. 159.
E-mail: Garkov2000@mail.ru
ORCID: https://orcid.org/0009-0007-9989-1526
Похожие статьи
